MINNEAPOLIS, Aug. 7 /PRNewswire/ -- AGA Medical Corporation (“AGA”) today announced that it has expanded its Board to seven (7) members with the election of Daniel Pelak, CEO of InnerPulse, Inc. and Terry Allison Rappuhn former CFO of Quorum Health Group, Inc to the Board of Directors.
“We are pleased to add Dan and Terry to the AGA Medical Board of Directors,” said Tommy Thompson, Chairman of the Board of AGA Medical. “They join a dynamic Board at a great company with world class products. Both bring an outstanding blend of healthcare experience on both the medical device and health care provider side. I look forward to working with them and the other members of the AGA Board to position the company for even greater success.” Tommy Thompson is a former U.S. Health and Human Services Secretary and four- term Governor of Wisconsin and is currently a partner at the law firm of Akin Gump Strauss Hauer & Feld.
Daniel Pelak is President and CEO of InnerPulse, Inc., a privately held company developing innovative cardiac rhythm management devices. Prior to his current position, Dan was President and CEO of Closure Medical, a manufacturer of innovative tissue glues designed to close cuts and wounds without the use of sutures or bandages. Closure Medical was acquired in 2005 by Johnson and Johnson. He also enjoyed a successful career at Medtronic where he held a series of positions with increasing responsibility in sales, marketing and general management.
Terry Alison Rappuhn is currently the project leader for Healthcare Financial Management Association’s PATIENT FRIENDLY BILLING(R) project, a national initiative to make financial communications with patients, clear, concise and patient focused. She has served as Chief Financial Office at Quorum Health Group, Inc, an owner and operator of healthcare systems nationwide. Terry also serves as a member of the Board of Directors of Genesis HealthCare Corporation. She started her career at Ernst and Young and is a CPA.
“Terry and Dan will be a terrific resource for the AGA management team and me,” said Franck Gougeon, President and CEO of AGA. “I look forward to tapping their extensive knowledge and experience as successful managers in the high growth healthcare industry. It is an exciting time at AGA and their advice and counsel, as well as the advice and counsel of their fellow Board members, will continue to play an important role in enabling the Company to take advantage of the many opportunities ahead.”
ABOUT AGA MEDICAL: AGA Medical Corporation, based in Golden Valley, Minnesota (just outside Minneapolis) is the leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the Company has developed and commercializes a series of devices that have revolutionized the treatment of the most common congenital “holes in the heart” such as atrial septal and patent foramen ovale defects. Over 500 articles have been published in peer reviewed medical publications that support the benefits of AGA Medical devices including improved patient outcomes, reduced length of stay and accelerated recovery times for the patient, AGA Medical devices have received regulatory approval and are marketed in over 90 countries with over 190,000 devices shipped to date. For more information visit www.amplatzer.com .
MEDIA CONTACT: Elie Jacobs Brunswick Group LLC 212.333-3810 ejacobs@brunswickgroup.com
AGA Medical Corporation
CONTACT: Elie Jacobs of Brunswick Group LLC for AGA Medical Corporation,+1-212-333-3810, or ejacobs@brunswickgroup.com
Web site: http://www.amplatzer.com//
